3 April 2024 - Today, the US FDA approved Zevtera (ceftobiprole medocaril sodium for injection) for the treatment of adults with Staphylococcus aureus bloodstream infections (bacteremia), including those with right-sided infective endocarditis; adults with acute bacterial skin and skin structure infections (ABSSSI); and adult and paediatric patients three months to less than 18 years old with community-acquired bacterial pneumonia.

Zevtera’s efficacy in treating ABSSSI was evaluated in a randomised, controlled, double-blind, multinational trial.

Read FDA press release